DOGWOOD ENROLLS FIRST 200 PATIENTS IN ONGOING HALNEURON® PHASE 2B CHEMOTHERAPY INDUCED NEUROPATHY TRIAL; TOP-LINE DATA EXPECTED IN FALL 2026

Reuters · 2d ago

Please log in to view news